Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of cancer"
DOI: 10.1016/j.ejca.2018.08.010
Abstract: AIM Androgen deprivation therapy (ADT) has long been the gold standard for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Clinical trials have demonstrated significant survival benefits when docetaxel (DOC) or abiraterone acetate (AA) and prednisone… read more here.
Keywords: prostate; hormone sensitive; metastatic hormone; sensitive prostate ... See more keywords
A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.
Sign Up to like & getrecommendations! Published in 2019 at "European urology oncology"
DOI: 10.1016/j.euo.2019.01.004
Abstract: BACKGROUND Following the recent publication of results from randomized trials that have demonstrated a survival benefit for the addition of docetaxel or abiraterone acetate to androgen deprivation therapy (ADT) in the treatment of metastatic prostate… read more here.
Keywords: adt; treatment; hormone sensitive; metastatic hormone ... See more keywords
Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard.
Sign Up to like & getrecommendations! Published in 2017 at "European urology"
DOI: 10.1016/j.eururo.2017.09.029
Abstract: Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition… read more here.
Keywords: abiraterone acetate; prostate cancer; hormone sensitive; metastatic hormone ... See more keywords
How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Sign Up to like & getrecommendations! Published in 2021 at "Indian Journal of Medical and Paediatric Oncology"
DOI: 10.1055/s-0041-1729725
Abstract: Androgen deprivation therapy (ADT) combined with docetaxel or antiandrogens (abiraterone, enzalutamide, or apalutamide) improved the outcomes in men with metastatic hormone-sensitive prostate cancer (mHSPC). When multiple options are available, the dilemma remains how to choose… read more here.
Keywords: metastatic hormone; sensitive prostate; prostate cancer; hormone sensitive ... See more keywords
Feasibility and efficacy of early docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in a rural health care setting
Sign Up to like & getrecommendations! Published in 2022 at "Scandinavian Journal of Urology"
DOI: 10.1080/21681805.2022.2028006
Abstract: Abstract Aim/Background The aim of this study was to evaluate the feasibility and efficacy, in terms of overall survival, of intensified upfront systemic therapy in patients with metastatic hormone-sensitive prostate cancer who lived in rural… read more here.
Keywords: metastatic hormone; feasibility efficacy; therapy; early docetaxel ... See more keywords
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Oncology"
DOI: 10.1093/annonc/mdy071
Abstract: Abstract Background Our prior Systemic Treatment Options for Cancer of the Prostate systematic reviews showed improved survival for men with metastatic hormone-naive prostate cancer when abiraterone acetate plus prednisolone/prednisone (AAP) or docetaxel (Doc), but not… read more here.
Keywords: systemic treatment; network; treatment; metastatic hormone ... See more keywords
Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyaa045
Abstract: BACKGROUND Cancer cachexia is associated with a poor prognosis. This study aimed to investigate the association between sarcopenia and survival in patients with metastatic hormone-sensitive prostate cancer. METHODS We retrospectively evaluated 197 patients diagnosed with… read more here.
Keywords: prostate cancer; hormone sensitive; metastatic hormone; sensitive prostate ... See more keywords
Systemic therapy in metastatic hormone-sensitive prostate cancer
Sign Up to like & getrecommendations! Published in 2022 at "Current Opinion in Supportive and Palliative Care"
DOI: 10.1097/spc.0000000000000622
Abstract: Purpose of review The landscape of metastatic hormone sensitive prostate cancer (mHSPC) has evolved rapidly in recent years with new data from landmark trials supporting upfront treatment intensification. The developments come not only on the… read more here.
Keywords: metastatic hormone; prostate cancer; therapy; hormone sensitive ... See more keywords
External validation of the prostascore model in patients with metastatic hormone‐sensitive prostate cancer recruited to the CHAARTED study
Sign Up to like & getrecommendations! Published in 2018 at "BJU International"
DOI: 10.1111/bju.14138
Abstract: To externally validate ‘prostascore’ in patients with metastatic hormone‐sensitive prostate cancer recruited to the phase III CHAARTED study. read more here.
Keywords: prostate cancer; patients metastatic; hormone sensitive; cancer recruited ... See more keywords
Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Urology"
DOI: 10.1111/iju.14568
Abstract: To evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer. read more here.
Keywords: men metastatic; deprivation therapy; metastatic hormone; androgen deprivation ... See more keywords
Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone‐sensitive prostate cancer with Gleason score ≥8
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Urology"
DOI: 10.1111/iju.14781
Abstract: We evaluated the impact of Gleason pattern 5 presence on prognosis among de novo metastatic hormone‐sensitive prostate cancer patients with a Gleason score ≥8. read more here.
Keywords: impact gleason; metastatic hormone; hormone sensitive; gleason pattern ... See more keywords